- Comprehensive overview of all aspects of the global pharmceutical industry

- Includes case studies of company operations, products and markets

- A broad range of industry statistics and data are included

- Gives a clear explanation of industry terminology

- Provides a brief overview of key regulatory processes and the official bodies

- Identifies the economic and social drivers that will shape companies this decade

Who should buy this report?

- Suppliers to the pharmaceutical industry

- Financial and business analysts

- Scientists recently entering the pharamaceutical industry

- Pharmaceutical and Biotech company graduate trainees

- Support staff in pharmaceutical companies

- Anyone working or involved with the global pharmaceutical industry

Contents

- Forward by Professor Rolf Krebs, DrMED, DTHC Vice-Chairman Boehringer Ingelheim

- A Brief History of the Pharmaceutical Industry

- The Pharmaceutical Industry Vital Statistics

- Market Dynaimics

- Drug Discovery

- Clinical Development

- Manufacturing

- Launch and Marketing

- Regulation

- What makes a company successful

- A glimpse of the future.

Published: January 2001

Pages: c.100

Author: Mark Greener

Publisher: Informa Group plc

Analgesia - Markets and Therapies discusses the science behind conventional analgesic drugs and how these therapies can be improved. The report highlights potential areas for advancement of analgesic drugs through a summary of the areas of research currently being investigated in experimental animal or man.

How will this report help me?

A comprehensive discussion of the analgesics in late stage development, including those recently launched, and an examination of their likely impact on the future shape of the analgesic market, including:

- Opiods - Cox-2 inhibitors - Disease Modifying Anti-Rheumatic Drugs (DMARDS) - Matrix metalloproteinase inhibitors (MMPI's) - Monoclonal antibodies - Triptans - Calcium antagonists - Nitric oxide - New indications for NSAIDS

An assessment of demand for analgesics in the US and UK markets, including data such as pain problems in acute hospitals, reasons for inability to provide analgesic of choice and leading causes of injuries to ambulatory patients;

An indispensable analysis of the main areas of growth for the analgesic market worldwide;

Estimations of the size of the main analgesic markets by value in the major geographic markets of the world, identifying new entrants and leading companies. Markets covered in depth include opiods, the migraine market, the local anaesthetic market and the over-the-counter market for analgesic;

A breakdown of the OTC analgesic markets in the following countries: USA, UK, Japan, Brazil, Germany, Spain, France, Canada and Italy

Asummary of the types of pain and sensitivities to present therapies, including post-operative pain, post-operative dental pain, visceral pain, migraine, labour pain, neuropathic pain, arthritic and cancer pain.

Published March 2000

Authors: Alex and Barbara Pleuvry

Publisher: Informa Group plc

Areas of coverage include:

- In-depth analysis of the strategy of the leading pharmaceutical companies

- Review of the key financial data company by company

- Ranking of the top pharmaceutical companies by ethical sales and by region

- Assessment of the Research & Development pipelines of each company

Essential reading for:

- Pharmaceutical manufacturers

- Strategic management consultancies with a pharmaceutical division

- Pharmaceuticals Investment analysts in banks

- Pharmaceutical Industry associations

Contents include:

- Ranking methodology

- Executive summary

- Strategic Profile of each pharmaceutical company ranked

- Conclusions

3 Volumes: USA/Japan/Europe

Published: October 2000

Format: CD-ROM

Author: Phil White

Publisher: Informa Group plc

Publisher: Informa Group plc

To assist readers in understanding the market's history and current situation, the Guide outlines the development of China's medical history, commerce, science and technology, and education in the past 20 years. The nine appendices provide additional detailed information on companies, registered products, and product pricing.

The book offers insight into the Chinese drug administration system, drug law, administration of registration, manufacture and distribution of drugs and pricing and its control. It also makes informed assessment on the impact of the ongoing reforms to the healthcare system and projects the future shape of the Chinese pharmaceutical industry.

The Guide is ideal for industry participants and analysts who want to learn about China's revised drug administration system and China's medical history. Chinese and foreign pharmaceutical enterprises will benefit from up-to-date information on new drug research and development, drug registration, manufacturing, distribution and utilisation, and investment in China.

Author(s): China Concept Consulting and The Information Centre of the State Drug

Published: June 2000

Publisher: Informa Group plc

Publisher: Informa Group plc

Publisher: Informa Group plc

E-Pharmacies in Europe: Will the Internet Revolutionise Drug Sales? is a timely publication that focuses on the role and attitudes of the key players which will be affected by e-pharmacy, and which will also drive its development.

The report sets out to evaluate the current situation and to look at how the picture may change in future

Topics covered include:

- Review of regulations surrounding on-line pharmaceutical sales

- Analysis of the parties opposing e-commerce and insight into their lobby groups

- Careful discussion of the role of chain pharmacies, drugstores and wholesalers

- Forecasts of the likely e-pharmacy market in Europe

E-Pharmacies in Europe: Will the Internet Revolutionise Drug Sales? will be useful reading for all involved in the fast-moving world of e-commerce and the pharmaceutical and consumer healthcare industries.

Contents include:

Chapter 1: Current status of e-pharmacy in Europe

Chapter 2: Regulatory barriers

Case study: Mail order pharmacy in Europe

Chapter 3: Can Europe learn from the US model?

Chapter 4: Key players in e-pharmacy in Europe

Chapter 5: Future developments

Chapter 6: The impact of e-pharmacy

Published: July, 2000

Author: Yvonne Martin

Publisher: Informa Group plc

Publisher: Informa Group plc

Publisher: Informa Group plc

Predicted by many to have even greater significance to the clinical medicine and biomedical research establishments as we enter into the 21st century, this report details how the role of Alternative and Complementary Healthcare (ACH) will expand in the decade of extensive progress in genomics and bioactives.

Answering key questions, this report:

- Assesses the benefits and potential risks of functional foods

- Reviews key questions on safety and efficacy

- Discusses the increasing acceptance from governments as they strive to restrict the growing costs of healthcare

- Analyses the growing questions and dilemmas facing pharmacists

- Understand why patients turn towards breakaway therapies

Key benefits:

- Learn about the promises of over 1300 alternative healing methods

- Comprehensive analysis into the upturn for unconventional therapies

- Unique assessments of the regulatory approaches to ACH in the US, Canada, Japan and Europe

- Develop your business strategy by being able to chart a course across the regulatory landscape for herbal products, nutraceuticals and dietary supplements

- Gain insights into clinical practice and its role in genomics and biomedicine

Published: January, 2000

Author: Gilbert Mertens

Publisher: Informa Group plc

Providing a comprehensive overview of the latest significant changes, including profiles of companies and products within this dynamic marketplace, this is a vital source of information for anyone needing to stay in touch.

This unique report answers all these questions and is essential reading for:

- Senior pharmaceutical executives

- Pharmaceutical marketing directors

- Strategy directors in the pharmaceuticals industry

- Senior executives from generic manufacturers

- Healthcare providers

- Healthcare insurers

- Consultants to the healthcare industry

This in-depth report:

- Covers all major issues relating to the generics industry including IPR, patent issues and regulatory background.

- Summarises the registration process for generic products in Europe, the USA and Japan.

- Profiles the major players in the generic market with up to date information.

- Provides country profiles of leading generic suppliers in the UK, Europe andAsian markets together with their respective market share.

- Analyses market size and growth data for the European, US and Japanes markets.

Published: August, 1999

Author: Paul Evers

Editor: Naomie de Andia

Publisher: Informa Group plc

This report provides a current review of the dynamically changing world of on-line healthcare consumers, professionals and organisations as they transform the delivery of healthcare.

It will benefit your business by giving you insight into the most successful E-strategies:

- Find out why the Internet works for DTC advertising

- Discover what other innovative pharmaceutical companies are doing online

- Learn how to develop strategies to cope with the constantly change environment of the Internet

- Discuss how to be connected internally and externally with your business partners and with consumers

- Find out how you can use the Internet to improve the drug development process

- Learn about new opportunities to increase awareness and access to clinical trials.

Key features of the report include:

- Analysis of the three main internet economic models: the advertising, E-commerce and transactional models;

- Latest developments in E-markets

- The results of the latest market intelligence surveys on internet users, E-commerce brand awareness and online sales

- Comparisons with strategies that work in other industries.

- Case studies highlight strategies that can be used to the greatest effect within the pharmaceutical industry.

drkoop.com, drugstore.com, on health.com, physiciansonline.com, planetRX.com, yourpharmacy.com

Published: January, 2000

Author(s): Team lead by Jivesh Sharma

Publisher: Informa Group plc

Providing essential information, this new report provides a step by step reference tool to all aspects of mergers and acquisitions.

Illustrating the changes from the early days of high margins and large-scale price premiums for innovative high tech acquisitions through to the increasing speed to acquire novel new drugs in the 21st century in a bid to reduce R&D and production costs.

Detailed examination of the key drivers:

- Concentration of the industry

- Information technology

- New drug discovery technologies

- Emerging economies and resurging diseases

- Innovative R&D

Analysis of key issues:

- The future of the OTC and Diagnostic sectors

- The Biotechnology markets and players key targets

- The re-segmentation of the industry

- The rise in DTC advertising for innovative drugs

- Acquisition targets and potential synergies to be gained

- Important factors when considering horizontal, vertical & concentric acquisitions

Features include:

- Tables highlighting the top ranked companies in Europe, the US and Japan.

- Step by step analysis of the key stages in acquisition procedures

- In-depth evaluations on the procedures used to analyse potential acquisition candidates

- Comprehensive coverage of the approaches used to calculate company value

- The stages and procedures involved in due diligence

- Tables highlighting selected new drugs approved in the US and NCEs launched in Europe

Published: February 2000

Author: Rudi D. Neirinckx

Publisher: Informa Group plc

Patients have organised themselves into patient advocacy groups on a grand scale and these have emerged as a key customer for the industry as they potentially hold a great deal of power and influence. Such 'added value' approaches are becoming common-place and the advent of abundant and well run patient advocacy groups has placed such company-patient group alliances to the top of the strategy agenda.

Features include:

- Chapters which outline the motives and business drivers for both groups that are encouraging such relationships

- Practical case studies of some of the better, more successful partnerships that have occurred and practical next steps for the industry and patient groups alike

- A review of the regulatory, legal and ethical considerations holding sway in each major area

- A directory of hundreds of known groups by geography and therapy-type

This report gives an overview of the changing dynamics taking place within the pharmaceutical industry world-wide and documents the rise of the patient (consumer) as a potent economic force in healthcare and a prime target for sustained competitive advantage for drug companies.

Published: May, 2000

Author: Fred Mills MBA, BSc (Hons), Dip.M

Publisher: Informa Group plc

Using clear language throughout, Pharmaceutical Regulation in Europe delivers straightforward information from a wealth of resources about every facet of regulation. It is mandatory reading for all who need to stay up to date with this changing area.

The EU regulatory framework governing the development, testing, manufacture and marketing of prescription pharmaceuticals within the European Community underwent a significant development on 1 January 1995 with the introduction of the EMEA.

This report provides a comprehensive update of all subsequent developments across the key areas of product registration, patents, advertising, packaging and pharmacovigilance.

Key benefits:

- Contains a useful summary of the main EU institutions, legal instruments, ICH process and workings of the EMEA

- Summarises procedures and directives currently regulating pharmaceutical production and sales within the EU including product registration, advertising and packaging, patents, good manufacturing, laboratory and clinical practice and pharmocovigilance

- Evaluates the strengths and weaknesses of alternative registration procedures

- Provides an insight into national variations in marketing restrictions, labelling, packaging and advertising regulations

- Calculates how long an NCE product has exclusivity and provides guidance on implementing a profit maximisation scheme

- Guidance on the registration of NCE products and an explanation of the GMP, GLP and GCP guidelines

- Guidance on effective post-marketing surveillance of an NCE product in accordance with those responsibilities identified by EU regulations

- Complemented by a glossary, tables and figures

Published: May, 2000

Author(s): Panos Kanavos & Christina Golna

Publisher: Informa Group plc

Principles for Effective Online Pharmaceutical Marketing is a new report wich provides step-by-step guidance on how to plan an effective online strategy. Starting with an examination of your current strategy the report will help you to harness the full power of the Internet to meet both the needs of your customers, and to fulfil your business and marketing objectives.

This report will help you to:

- Develop strategies to market pharmaceutical products on line

- Discover how to plan an effective online presence that meets marketing objectives and gets results

- Identify the key legal and regulatory issues affecting your Web site

- Discover how to expoit the Internet for customer relationship building

- Identify marketing opportunities on the Internet

- Promote your Web site to reach your target audience

- Examine strategies for measuring the effectiveness of your Web site.

Published: February 2000

Author: Andre K Bates

Publisher: Informa Group plc

It shows you how to evaluate the uniqueness of an opportunity, together with key aspects involved in the negotiation, the development scope of a partnership and the financial returns involved in any venture.

Key Benefits:

- Highlights the essential winning factors in determining successful pharmaceutical strategies and product opportunities

- Evaluates licensing strategies at every stage from concept through to delivery

- Provides a full explanation of corporate strategies, business development strategies, due diligence, valuation techniques, negotiation issues and key terms in the agreement

- Provides guidance on defining business development strategies and business potential

- Identifies potential licensing partners

- Evaluates the different types of agreements available

- Assesses financial considerations

- Offers advice on overcoming common pitfalls

Published: April, 1999

Author(s): Paul Ranson, Richard Binns, Bryan Driscoll & Sharon Finch

Publisher: Informa Group plc

High amounts of inventory held by pharmaceutical manufacturers is one of the most costly elements in supply chain, electronic exchange of data and e-commerce will allow a significant shift in the supply chain, as manufacturing and supply flows are driven by actual demand.

Although wholesalers have lagged behind manufacturers in their enthusiasm for the internet, the report shows that all have developed on-line capabilities which can be accessed exclusively by customers and offer direct ordering, sales overviews, new drug information and stock control services. The pharmaceutical market is becoming increasingly integrated as a result of industry globalisation, regulatory harmonisation, greater price convergence, the single currency and more standardised product ranges.

The Future of European Pharmaceutical Distribution is a new report providing fully researched analysis on key distribution issues and the major challenges of e-commerce and cross-border supply as we enter into the 21st century.

Key benefits:

- Understand the impact of IT on managing distribution in Europe

- Analyse changing impulses in supply chain demand

- Anticipate and exploit price differentials and exchange rate fluctuations

- Gain insights into the consolidation process amongst wholesalers

- Assess the potential of a single European market

- Evaluate the impact of the European Union on your business strategy

- Exclusive company profiles of the leading European wholesalers

- Extensive analysis of the regulations and barriers to cross border distribution

- Country distribution market profiles, including CEE countries

- Invaluable insights into the future of EU policy and cross border supply

- Latest analysis of recent cross border mergers, acquisitions and joint ventures

- The impact of the EMU and Parallel traders

Answering key questions, this report is essential for formulating European manufacturing, distribution and sales strategies:

- Will manufacturers move to Pan-Continental pricing and distribution?

- What will be the role of pre-wholesaling?

- How are distributors harnessing IT to build knowledge of their customer base?

- Will re-engineering of manufacturing operations and locations have a knock-on effect on distributors?

- Why are wholesalers competing in the pharmacy sector?

- How are wholesalers focusing on their core competencies?

Published: April, 2000

Author: Yvonne Martin

Publisher: Informa Group plc

Vital questions answered include;

- How will the Roche provisions be resolved in Europe and how has the Hatch-Waxman act effected the industry

- What the decline in inventor exclusivity means for the marketing of new patented drugs

- Which middle income countries are doing to ensure fair patent protection for foreign companies

- What is the role of the EC's Biotechnology Patent Directive

Published: June, 2000

Publisher: Informa Group plc